Cargando…
A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects
The aim of the study was to study the PK of AST2818 tablets after one oral dose in healthy male subjects on an empty stomach and in a postprandial state and to evaluate the effect of food on AST2818 bioavailability. Sixteen healthy Chinese male subjects were randomly divided into two groups: a fasti...
Autores principales: | Zhu, Songlin, Deng, Jun, Tang, Qi, Heng, Jianfu, Qu, Jingjing, Chen, Yong, Chen, Xue, Yang, Nong, Liu, Xiaobao, Li, Kunyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757978/ https://www.ncbi.nlm.nih.gov/pubmed/33680007 http://dx.doi.org/10.22037/ijpr.2020.113112.14116 |
Ejemplares similares
-
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
por: Liu, Xiao-yun, et al.
Publicado: (2020) -
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022) -
Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway
por: Qu, Jingjing, et al.
Publicado: (2019) -
Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway
por: Qu, Jingjing, et al.
Publicado: (2019) -
Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
por: Cheng, Daoan, et al.
Publicado: (2022)